Fundraising FoxEuclises
4 known investors
Find your way into Euclises
Sign up to see every warm intro you have to Euclises
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Euclises team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.
Investors · 4
Cultivation CapitalreportedSt. Louis · $100K – $3.5M
How we know: funding news · the VCSheet dataset · Not right? Tell us
Missouri Technology CorporationreportedSt. Louis
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Euclises do?
- Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.
- Who are Euclises's investors?
- Euclises's investors include Argonautic Ventures, iSelect Fund, Cultivation Capital, Missouri Technology Corporation.